Headquartered in Wilmington, MA Fiscal year ends December NYSE: CRL criver.com
Charles River Laboratories International, Inc. provides essential products and services that support pharmaceutical and biotechnology companies, government agencies, and academic institutions in accelerating their research and drug development efforts. The company operates through three reportable segments: Research Models and Services (RMS), which provides research models and related services; Discovery and Safety Assessment (DSA), which offers regulated safety assessment and discovery services for drug candidates; and Manufacturing Solutions, which provides testing services for manufactured biologics and pharmaceuticals, including microbial solutions and biologics testing. The company serves the full spectrum of drug development from discovery through safe manufacture, with a global footprint and deep scientific expertise. Charles River has been actively refining its portfolio through divestitures of its CDMO and Cell Solutions businesses and certain European Discovery Services sites, while investing in capabilities such as AI-enabled digital pathology, Next Generation Sequencing via its PathoQuest acquisition, and strategic collaborations with clients like Eli Lilly and Arovella Therapeutics. Updated
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising…
Pre-Market Stock Futures: Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX | SPCX Price Prediction) or SpaceX IPO rush is starting to fade…
Pre-Market Stock Futures: Futures are trading higher after yet another winning day for Wall Street, as all major indices finished the day higher after starting the session lower. Once again, all four…
Citi swept through its life science tools and diagnostics coverage on Wednesday, opening a 90-day upside catalyst watch on Agilent Technologies (NYSE:A | A Price Prediction) while trimming its price target on…
These are the top analyst upgrades, downgrades, and initiations seen before markets opened on Tuesday, July 11, 2023.
Friday's top analyst upgrades and downgrades included AppLovin, CarMax, Cinemark, Diamondback Energy, Enovix, Etsy, Graphic Packaging, Home Depot, Intel, Lucid, Nvidia, Teladoc Health, Walgreen Boots Alliance and Workday.
After a week of modest gains, Friday's premarket session was shaping up as a downer. All three major indexes were trading lower.
U.S. markets are on track for a slightly higher open Tuesday, but Tesla is struggling again after reporting December-quarter deliveries that fell short of expectations.
Friday’s top analyst upgrades and downgrades included America Movil, Ball, Ciena, Costco Wholesale, Dish Network, Fortinet, Infinera, Levi Strauss, Match, RingCentral, Robinhood Markets and Yum! Brands.
Friday's top analyst upgrades and downgrades included Annaly Capital Management, Carnival, Deere, Freeport-McMoRan, Honest Company, Royal Caribbean Cruises, Shoals Technologies, Take-Two Interactive Software, Toast and Yum China.
Friday's top analyst upgrades and downgrades included Altice USA, Applied Materials, Block, Coeur Mining, Consolidated Edison, Fastly, Shopify, SM Energy, Tata Motors and Wingstop.
Jefferies is out with its first top growth stock calls for 2021. These four top stock picks could be massive long-term winners, as they have significant catalysts that can drive growth for…
These four high-conviction health care stock ideas from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest…
Thursday's top analyst upgrades and downgrades included BigCommerce, Exxon, FedEx, Penn National, Rio Tinto, Trillium, Zscaler.
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Ciena, CommVault Systems, Dollar General, JD.com, Kroger, Nucor, Target and Walmart.
Charles River Laboratories International, Inc. provides essential products and services that support pharmaceutical and biotechnology companies, government agencies, and academic institutions in accelerating their research and drug development efforts.
24/7 Wall St.'s 12-month price target for CRL is $326.71, rated Buy. The Wall Street consensus target is $310.53. CRL price prediction →
